PALO ALTO, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the shareholders of Denali Capital Acquisition Corp (“Denali”) approved th ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Presents Scilex Holding Company's unaudited consolidated financial statements and notes on operations, accounting, liquidity, and recent events [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a snapshot of the company's financial position, detailing assets, liabilities, and stockholders' deficit at specific points in time Condensed Consolidated Balance Sheets (in thousands) | ASSETS (in thousands) | June 30, 2025 | December 31, 2024 | | :-------------------- | :------------ | :------------------ | | Cash and cash equivalents | $4,099 | $3,272 | | Accounts receivable, net | $16,767 | $26,442 | | Inventory | $2,519 | $2,436 | | Prepaid expenses and other current assets | $10,286 | $9,397 | | **Total current assets** | **$33,671** | **$41,547** | | Property and equipment, net | $705 | $708 | | Operating lease right-of-use asset | $1,868 | $2,225 | | Intangibles, net | $31,443 | $32,453 | | Investments | $2,468 | $2,420 | | Goodwill | $13,481 | $13,481 | | Other long-term assets | $119 | $119 |\ | **Total assets** | **$83,755** | **$92,953** | | | | | | LIABILITIES AND STOCKHOLDERS' DEFICIT (in thousands) | June 30, 2025 | December 31, 2024 | | :-------------------- | :------------ | :------------------ | | Accounts payable | $59,155 | $52,620 | | Accrued payroll | $1,633 | $1,505 | | Accrued rebates and fees | $192,940 | $162,517 | | Accrued expenses | $6,548 | $2,841 | | Current portion of deferred consideration | $427 | $447 | | Debt, current | $39,871 | $34,876 | | Purchased revenue liability, current | $4,590 | $4,115 | | Current portion of operating lease liabilities | $768 | $714 | | **Total current liabilities** | **$305,932** | **$259,635** | | Long-term portion of deferred consideration | $2,240 | $2,448 | | Debt, net of issuance costs | — | $845 | | Purchased revenue liability, net of current portion | $3,010 | $2,685 | | Derivative liabilities | $20,269 | $18,303 | | Operating lease liabilities, net of current portion | $1,126 | $1,523 | | Other long-term liabilities | $165 | $155 | | **Total liabilities** | **$332,742** | **$285,594** | | **Total stockholders' deficit** | **$(248,987)** | **$(192,641)** | | **Total liabilities and stockholders' deficit** | **$83,755** | **$92,953** | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This section details the company's financial performance over specific periods, showing revenues, expenses, and net loss Condensed Consolidated Statements of Operations (in thousands, except per share) | Metric (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net revenue | $9,896 | $16,370 | $14,900 | $27,254 | | Cost of revenue | $3,272 | $4,390 | $4,656 | $8,230 | | Research and development | $6,187 | $2,004 | $8,643 | $5,112 | | Selling, general and administrative | $19,841 | $24,598 | $47,901 | $53,876 | | Intangible amortization | $1,008 | $1,001 | $2,010 | $2,028 | | Legal settlements | $95 | — | $95 | $(6,891) | | Total net operating costs and expenses | $30,403 | $31,993 | $63,305 | $62,355 | | Loss from operations | $(20,507) | $(15,623) | $(48,405) | $(35,101) | | Loss on derivative liability | $12,375 | $15,284 | $1,966 | $15,741 | | Change in fair value of debt and liability instruments | $8,366 | $6,099 | $14,480 | $10,004 | | Interest expense, net | $2,682 | $571 | $5,163 | $1,102 | | Loss on foreign currency exchange | $99 | $5 | $95 | $11 | | Total other expense | $23,522 | $21,959 | $21,704 | $26,858 | | Loss before income taxes | $(44,029) | $(37,582) | $(70,109) | $(61,959) | | Income tax expense | $19 | — | $19 | — | | Net loss | $(44,048) | $(37,582) | $(70,128) | $(61,959) | | Deemed dividend | $(43,753) | — | $(43,753) | — | | Net loss attributable to common stockholders | $(86,061) | $(37,582) | $(112,141) | $(61,959) | | Net loss per share attributable to common stockholders — basic and diluted | $(7.42) | $(7.67) | $(9.68) | $(15.49) | | Weighted average number of shares during the period — basic and diluted | 11,595 | 4,901 | 11,580 | 3,999 | [Condensed Consolidated Statements of Stockholders' Deficit](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Deficit) This section outlines changes in the company's equity over time, including net loss, stock-based compensation, and treasury stock movements - The company's total stockholders' deficit increased from **$(192,641) thousand** as of December 31, 2024, to **$(248,987) thousand** as of June 30, 2025, primarily due to a net loss of **$(42,308) thousand** and a deemed dividend of **$(43,753) thousand** related to anti-dilution adjustments for Penny Warrants upon a Reverse Stock Split[25](index=25&type=chunk)[23](index=23&type=chunk)[36](index=36&type=chunk) - Stock-based compensation contributed **$3,314 thousand** and **$3,279 thousand** to additional paid-in capital during the periods ending March 31, 2025, and June 30, 2025, respectively[25](index=25&type=chunk) - Treasury stock decreased from **$(90,522) thousand** to **$(76,915) thousand**, reflecting transfers for Tranche B Notes deferral, Gloperba Ex-U.S. License, and Oramed Note maturity extension[25](index=25&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section presents the cash inflows and outflows from operating, investing, and financing activities, showing the net change in cash Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :----------------------------- | :----------------------------- | | Net cash proceeds from operating activities | $13,057 | $11,702 | | Net cash used for investing activities | $(548) | $(300) | | Net cash used for financing activities | $(11,682) | $(6,465) | | Net change in cash, cash equivalents and restricted cash | $827 | $4,937 | | Cash, cash equivalents and restricted cash at beginning of period | $3,272 | $4,729 | | Cash, cash

PALO ALTO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the registration statement on Form S-4 (the "Registration Statement"), related to the previously announced proposed business combination (the "Bu ...

Core Insights - Scilex Holding Company announced a publication regarding GLOPERBA dosing adjustments in a peer-reviewed journal, emphasizing its focus on non-opioid pain management products for various conditions [1][5] Company Overview - Scilex Holding Company is dedicated to acquiring, developing, and commercializing non-opioid pain management products aimed at treating acute and chronic pain, neurodegenerative diseases, and cardiometabolic diseases [1][6] - The company’s commercial products include ZTlido, ELYXYB, and GLOPERBA, with GLOPERBA being the first and only liquid oral version of colchicine for gout flare prophylaxis [6][9] Product Details - GLOPERBA allows for precision dosing and is particularly beneficial for over 70% of gout patients who have comorbid conditions requiring dose adjustments [2][4] - The publication highlights the importance of precise dosing for patients with renal impairment, suggesting specific dosages of 0.48 mg for moderate and 0.3 mg for severe renal impairment to maintain therapeutic levels and enhance safety [4][5] Clinical Significance - The publication is expected to provide essential data to guide clinical dosing of colchicine in patients suffering from gout and chronic renal failure, addressing a significant clinical need [5]

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 Scilex Holding Company For the transition period from to Commission File Number 001-39852 (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of Incor ...

Core Viewpoint - Scilex Holding Company has regained compliance with Nasdaq's minimum closing bid price requirement, maintaining a minimum closing bid price of $1.00 per share for at least ten consecutive trading days as of April 30, 2025 [1] Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][5] - The company targets high unmet needs and large market opportunities with non-opioid therapies to improve patient outcomes [3] Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief associated with postherpetic neuralgia [3] - ELYXYB®, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3] - Gloperba®, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [3] Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [4] - SP-103, a next-generation formulation of ZTlido for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status from the FDA [4] - SP-104, a low-dose delayed-release naltrexone hydrochloride for fibromyalgia treatment [4]

Core Insights - Scilex Holding Company has received FDA approval for Orphan drug designation for colchicine to treat pericarditis, enhancing its portfolio in non-opioid pain management products [1][3]. Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, with a commitment to improving patient outcomes [5][10]. - The company is headquartered in Palo Alto, California [9][11]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8% for neuropathic pain relief [5][7]. - ELYXYB, an oral solution for acute migraine treatment [5][7]. - Gloperba, the first liquid oral version of colchicine for gout flare prophylaxis [6][7]. - The company has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections targeting lumbosacral radicular pain, which has completed Phase 3 studies [8]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completing Phase 2 trials [8]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [8]. Regulatory Insights - The Orphan Drug Act allows the FDA to grant orphan designation to drugs intended for rare diseases, which can lead to seven years of market exclusivity upon first approval [3].

Core Viewpoint - Scilex Holding Company will implement a reverse stock split at a ratio of 1-for-35 effective April 15, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as treatments for neurodegenerative and cardiometabolic diseases through a proposed joint venture with IPMC Company [1][8][9]. - The company’s commercial products include ZTlido®, ELYXYB®, and Gloperba®, targeting high unmet needs in pain management [9][10]. Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 243 million to about 6.9 million [4]. - The split will not affect the authorized number of shares, and stockholders will receive cash payments for any fractional shares [3][5]. - The reverse stock split was approved by stockholders on March 19, 2025, with the board of directors selecting the 1-for-35 ratio on April 3, 2025 [5]. Trading Information - Post-split, Scilex's common stock will continue trading on The Nasdaq Capital Market under the symbol "SCLX" with a new CUSIP number [2]. - Continental Stock Transfer & Trust Company will manage the exchange process for stockholders [6].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of Incorporat ...

Core Viewpoint - Scilex Holding Company is actively pursuing an appeal against a lower court decision that ruled in favor of Aveva Drug Delivery Systems, asserting that Aveva infringes on Scilex's ZTlido patents [1][3][4] Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for both acute and chronic pain [6][10] - The company has a portfolio that includes ZTlido, ELYXYB, and Gloperba, targeting high unmet medical needs in pain management [6][10] Legal Proceedings - In May 2022, Scilex was notified of Aveva's submission of an Abbreviated New Drug Application (ANDA) that may infringe on Scilex's ZTlido patents, leading to a patent infringement lawsuit filed in June 2022 [2] - The U.S. District Court ruled in July 2024 that Aveva's proposed product did not infringe Scilex's patents, prompting Scilex to appeal the decision [3][4] Intellectual Property - Scilex maintains confidence in the strength and validity of its ZTlido intellectual property and believes that Aveva is infringing on its patents [4] - The company is pursuing additional patents for follow-on programs to further protect its intellectual property portfolio [4]